Stephen Knight joined F-Prime Capital in 2003 where he serves as President and Managing Partner. He has worked in the pharmaceutical and biotechnology industries for over 30 years and invests broadly across healthcare.  Steve serves on the Board of Directors of  Aerium Therapeutics, Atalanta Therapeutics, Ensoma, Genomics plc, Leyden Labs, Paradigm, Proof Diagnostics, Pulmocide and Skyline Therapeutics.  Steve previously served on the boards of several private and public health care companies including Beam Therapeutics (NASDAQ: BEAM),  Blueprint Medicines (NASDAQ: BPMC), Denali Therapeutics (NASDAQ: DNLI), FoldRx Pharmaceuticals (acquired by Pfizer), Innovent Biologics (1801.HK), Iora Health (acquired by One Medical), Ironwood Pharmaceuticals (NASDAQ: IRWD), NextWave Pharmaceuticals (acquired by Pfizer), Prime Medicine (NASDAQ: PRME), Proteostasis Therapeutics (NASDAQ: PTI), Respivert, Ltd (acquired by J&J), Sana Biotechnology (NASDAQ: SANA) and Semma Therapeutics (acquired by Vertex).

Prior to joining F-Prime Capital, Steve held various senior management roles in private and public biotechnology and consulting companies. He also was a researcher at AT&T Bell Laboratories, the National Institutes of Health, and Yale University. He holds an M.D. from the Yale University School of Medicine, an M.B.A. from the Yale School of Organization and Management and received a B.S. in biology from Columbia University, graduating summa cum laude and Phi Beta Kappa.